| __timestamp | Amphastar Pharmaceuticals, Inc. | Celldex Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 20622000 |
| Thursday, January 1, 2015 | 46974000 | 33837000 |
| Friday, January 1, 2016 | 47298000 | 35979000 |
| Sunday, January 1, 2017 | 50918000 | 25003000 |
| Monday, January 1, 2018 | 58044000 | 19269000 |
| Tuesday, January 1, 2019 | 63109000 | 15426000 |
| Wednesday, January 1, 2020 | 65157000 | 14456000 |
| Friday, January 1, 2021 | 68920000 | 20488000 |
| Saturday, January 1, 2022 | 66592000 | 27195000 |
| Sunday, January 1, 2023 | 80393000 | 30914000 |
Unleashing the power of data
In the competitive landscape of pharmaceuticals, understanding spending patterns is crucial. Over the past decade, Amphastar Pharmaceuticals, Inc. and Celldex Therapeutics, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. Amphastar's SG&A expenses have surged by approximately 99% from 2014 to 2023, reflecting a strategic investment in growth and operations. In contrast, Celldex's spending has been more volatile, peaking in 2016 and then stabilizing, with a modest increase of about 50% by 2023. This divergence highlights Amphastar's aggressive expansion strategy compared to Celldex's more conservative approach. As the pharmaceutical industry continues to evolve, these spending patterns offer insights into each company's priorities and market positioning. Investors and analysts should consider these trends when evaluating the financial health and strategic direction of these companies.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Celldex Therapeutics, Inc.
Selling, General, and Administrative Costs: argenx SE vs Amphastar Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Biogen Inc. and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Amphastar Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs Amphastar Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Celldex Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Xenon Pharmaceuticals Inc. or Celldex Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.
Vericel Corporation and Celldex Therapeutics, Inc.: SG&A Spending Patterns Compared
Arrowhead Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Breaking Down Revenue Trends: Amphastar Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.